159 / 188
Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
MS-84
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
2002;347:1999-2009. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/12490681.
240. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression
profiling predicts clinical outcome of breast cancer. Nature
2002;415:530-536. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/11823860.
241. Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the
70-gene signature for adjuvant chemotherapy in early breast cancer.
Breast Cancer Res Treat 2010;120:655-661. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/20204499.
242. Kunz G. Use of a genomic test (MammaPrint) in daily clinical
practice to assist in risk stratification of young breast cancer patients.
Arch Gynecol Obstet 2011;283:597-602. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/20383789.
243. Ishitobi M, Goranova TE, Komoike Y, et al. Clinical utility of the 70-
gene MammaPrint profile in a Japanese population. Jpn J Clin Oncol
2010;40:508-512. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/20110242.
244. Mook S, Knauer M, Bueno-de-Mesquita JM, et al. Metastatic
potential of T1 breast cancer can be predicted by the 70-gene
MammaPrint signature. Ann Surg Oncol 2010;17:1406-1413. Available
at:
http://www.ncbi.nlm.nih.gov/pubmed/20094918 .245. A phase III, randomized clinical trial of standard adjuvant
endocrine therapy +/-chemotherapy in patients with 1-3 positive nodes,
hormone receptor-positive and HER2-negative breast cancer with
recurence score (RS) of 25 or less. RXPONDER: A clinical trial RX for
positive node, endocrine responsive breast cancer. Clincial Trial ID
NCT01272037. Available at:
http://clinicaltrials.gov/show/NCT01272037.
246. A phase III, randomized, double-blind, placebo-controlled clinical
trial to evaluate the efficacy and safety of pertuzumab + trastuzumab +
docetaxel vs. placebo + trastuzumab + docetaxel in previously
untreated HER2-positive metastatic breast cancer. Trial
ID:NCT00567190. Available at:
www.clinicaltrials.gov
.
247. MINDACT (Microarray In Node-Negative and 1 to 3 positive lymph
node disease may avoid chemotherapy): A prospective, randomized
study comparing the 70-Gene signature with the common clinical-
pathological criteria in selecting patients for adjuvant chemotherapy in
breast cancer with 0 to 3 positive nodes. Clinical Trial ID:
NCT00433589. Available at:
http://clinicaltrials.gov/ct2/show/NCT00433589?term=NCT00433589&rank=1
.
248. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive
value of the 21-gene recurrence score assay in postmenopausal
women with node-positive, oestrogen-receptor-positive breast cancer
on chemotherapy: a retrospective analysis of a randomised trial. Lancet
Oncol 2010;11:55-65. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/20005174.
249. Hormone therapy with or without combination chemotherapy in
treating women who have undergone surgery for node-negative breast
cancer (The TAILORx Trial). Clinical Trial ID: NCT00310180. Available
at:
http://clinicaltrials.gov/ct2/show/NCT00310180?term=TAILORx&rank=2.
250. Swain SM, Wilson JW, Mamounas EP, et al. Estrogen receptor
status of primary breast cancer is predictive of estrogen receptor status
of contralateral breast cancer. J Natl Cancer Inst 2004;96:516-523.
Available at:
http://www.ncbi.nlm.nih.gov/pubmed/15069113.
251. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor
status and outcomes of modern chemotherapy for patients with node-
positive breast cancer. JAMA 2006;295:1658-1667. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/16609087.
252. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy
and timing of tamoxifen in postmenopausal patients with endocrine-